Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Immunicon, BMS Enter Biomarker Research Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Immunicon, BMS Enter Biomarker Research Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Immunicon Corp. has entered into a research services agreement with Bristol-Myers Squibb (BMS) involving protein and molecular targets associated with circulating tumor cells (CTCs).

Leon Terstappen, M.D., Ph.D., chief scientific officer of Immunicon said, “The list of pharmaceutical partners and biomarkers continues to expand. Our collaborations span across protein biomarkers, phosphoproteins and a variety of FISH assays to study gene amplification in a number of different carcinomas. We believe that our development work will advance the understanding of cancer biology as well as accelerate the time to market for promising new drugs.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters